Trial Profile
A Prospective Observational Study of Proton Stereotactic Body Radiation Therapy and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 08 Sep 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 31 Aug 2022 Status changed from active, no longer recruiting to discontinued due to failure to accrue.
- 31 Mar 2021 Status changed from recruiting to active, no longer recruiting.
- 01 Jun 2018 Status changed from not yet recruiting to recruiting.